For decades, medical centers have upheld a tradition of public education and clinical excellence, translating complex biomedical concepts into actionable guidance. The International Classification of Diseases (ICD) coding system has been a cornerstone of this effort, enabling standardized documentation of disease states across populations. This legacy extends to pharmacovigilance, where precise coding of adverse drug effects is essential for monitoring drug safety. The coding reference for autoimmune hepatitis exemplifies how a diagnostic label originally developed for clinical settings now supports occupational health surveillance and pharmaceutical risk assessment. (https://www.who.int/classifications/icd/en/)
As the informational infrastructure matured, its applications expanded beyond descriptive health education. The same rigorous methodologies used to catalog disease states have become indispensable in pharmacovigilance, where precise coding of adverse effects is essential for monitoring drug safety. This evolution brings us to a more specialized concern: the occupational exposure context. Workers in pharmaceutical manufacturing, healthcare delivery, and related industries may encounter active pharmaceutical ingredients or chemical intermediates in ways that differ fundamentally from therapeutic use. The coding reference for autoimmune hepatitis, as one example among many, illustrates how a diagnostic label originally developed for clinical settings now carries additional relevance in workplace health surveillance. Transitioning from general health literacy to this occupational lens requires recognizing that exposure pathways, dose-response relationships, and risk communication strategies demand distinct analytical frameworks—yet they remain rooted in the same commitment to accurate, neutral, and scientifically grounded information that defined the original legacy.
Autoimmune hepatitis (AIH) is a chronic, immune-mediated inflammatory disease of the liver characterized by elevated transaminases, hypergammaglobulinemia (predominantly IgG), and the presence of specific autoantibodies, including antinuclear antibodies (ANA), smooth muscle antibodies (SMA), and anti-liver kidney microsomal type 1 antibodies (anti-LKM-1). The clinical presentation ranges from asymptomatic elevation of liver enzymes to acute hepatitis, fulminant hepatic failure, or chronic progressive fibrosis leading to cirrhosis. Diagnosis requires exclusion of other causes of liver disease, including viral hepatitis, alcohol-induced injury, metabolic dysfunction-associated steatotic liver disease, and drug-induced liver injury. Liver biopsy is the gold standard for confirming the diagnosis, demonstrating interface hepatitis, plasma cell infiltration, and hepatocyte rosette formation. The International Autoimmune Hepatitis Group (IAIHG) scoring system, both in its original and simplified forms, is used to support the diagnosis, integrating clinical, laboratory, and histological features.
Pharmaceutical agents are recognized triggers of autoimmune hepatitis, either by unmasking latent autoimmunity or by inducing a de novo immune response directed against hepatocytes. The most commonly implicated drugs include minocycline, nitrofurantoin, hydralazine, methyldopa, and the tumor necrosis factor-alpha (TNF-α) inhibitors such as infliximab and adalimumab. Additionally, immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab, ipilimumab) used in oncology have been associated with a distinct form of immune-mediated hepatitis that shares histologic features with AIH. The pharmacology of these agents varies: minocycline and nitrofurantoin are antimicrobials with known hepatotoxic potential; hydralazine and methyldopa are antihypertensives; TNF-α inhibitors modulate inflammatory cytokine pathways; and checkpoint inhibitors block inhibitory T-cell receptors, thereby enhancing anti-tumor immunity but also breaking peripheral immune tolerance. The adverse effect profile for each drug includes hepatotoxicity, but the specific induction of autoimmune hepatitis is a rare, idiosyncratic reaction that is not dose-dependent and typically occurs after months to years of exposure, although checkpoint inhibitor-related hepatitis can appear within weeks of treatment initiation.
The mechanistic pathways by which pharmaceuticals induce autoimmune hepatitis are not fully delineated but involve several plausible, evidence-based hypotheses. First, drug or its reactive metabolites may act as haptens, binding to hepatocyte proteins and creating neoantigens that are recognized by the immune system as foreign, thereby triggering a T-cell-mediated attack. Second, molecular mimicry may occur, where drug-derived peptides share structural homology with self-antigens on hepatocytes, leading to cross-reactive immune responses. Third, drugs may alter the expression of major histocompatibility complex (MHC) class II molecules on hepatocytes, converting them into antigen-presenting cells and facilitating the activation of CD4+ T-helper cells. Fourth, for immune checkpoint inhibitors, the blockade of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) removes critical inhibitory signals, allowing autoreactive T-cells that were previously suppressed to become activated and infiltrate the liver. Genetic susceptibility, particularly the presence of HLA-DR3 and HLA-DR4 alleles, is a known risk factor for spontaneous AIH and likely also predisposes to drug-induced autoimmune hepatitis. The final common pathway involves the recruitment of effector T-cells, natural killer cells, and macrophages, leading to hepatocyte apoptosis, necrosis, and the characteristic histological pattern of interface hepatitis.
Regulatory safety communications and product labeling for the implicated pharmaceuticals include warnings about hepatotoxicity and, in some cases, specifically mention autoimmune hepatitis as a potential adverse reaction. For example, the prescribing information for minocycline includes a warning about autoimmune syndromes, including hepatitis, and recommends monitoring for symptoms such as jaundice, dark urine, and elevated liver enzymes. Similarly, the labeling for nitrofurantoin warns of acute and chronic hepatic reactions, including autoimmune hepatitis, and advises discontinuation if liver injury is suspected. For immune checkpoint inhibitors, the U.S. Food and Drug Administration (FDA) has issued warnings regarding immune-mediated hepatitis, which can be severe or fatal, and recommends monitoring liver function tests before and during treatment. These safety communications emphasize the importance of early recognition and prompt management, which typically involves discontinuation of the offending drug and initiation of immunosuppressive therapy, such as corticosteroids or azathioprine, in cases that do not resolve spontaneously. The risk of autoimmune hepatitis is considered rare for most drugs, but the consequences can be serious, including progression to cirrhosis or liver failure, necessitating vigilant clinical monitoring. (https://www.fda.gov/drugs/drug-safety-and-availability)
For affected patients, the diagnosis of drug-induced autoimmune hepatitis is coded using the ICD-10-CM system. The primary code for autoimmune hepatitis is K75.4 (Autoimmune hepatitis). However, when the condition is attributable to a pharmaceutical agent, the coding guidelines require the use of an additional code from the T36-T50 range to identify the specific drug and the adverse effect. For example, adverse effects of minocycline would be coded as T36.4X5A (Adverse effect of tetracyclines, initial encounter), and nitrofurantoin would be coded as T37.8X5A (Adverse effect of other systemic antibiotics, initial encounter). For immune checkpoint inhibitors, the appropriate code would be T45.1X5A (Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter). The external cause code is not required for adverse effects, as the drug itself is the cause. Additionally, if the patient has a history of drug-induced autoimmune hepatitis that has resolved, a personal history code (Z87.19, Personal history of other diseases of the digestive system) may be used. For pathology and laboratory coding, liver biopsy findings are reported using CPT codes (e.g., 47000 for percutaneous liver biopsy) and relevant gene expression or autoantibody tests (e.g., ANA, SMA, anti-LKM-1) are coded with specific laboratory CPT codes. Accurate coding is essential for documenting the causal relationship between the pharmaceutical and the adverse health effect, facilitating appropriate clinical management and pharmacovigilance.
The timeline between pharmaceutical exposure and the onset of autoimmune hepatitis varies significantly depending on the drug class. For minocycline and nitrofurantoin, the onset is typically subacute to chronic, with symptoms appearing after several months to years of continuous therapy. In contrast, immune checkpoint inhibitor-induced hepatitis can occur acutely, often within 6 to 14 weeks after the first dose, although later presentations have been reported. The latency period is a critical diagnostic clue; a temporal association between drug initiation and liver injury, along with improvement upon drug withdrawal, supports the diagnosis. However, in some cases, autoimmune hepatitis may persist or even first manifest after drug discontinuation, complicating the causal attribution. Documented health outcomes range from complete resolution after drug cessation and short-term immunosuppression to chronic active hepatitis requiring long-term therapy, and in rare cases, progression to cirrhosis or acute liver failure necessitating transplantation. The severity of outcomes is influenced by the promptness of drug withdrawal, the degree of liver injury at presentation, and the patient's underlying genetic predisposition. Therefore, clinicians should maintain a high index of suspicion for drug-induced autoimmune hepatitis in any patient presenting with liver enzyme elevation while on a potentially offending medication, and should document the exposure timeline meticulously to support diagnostic and coding accuracy.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.
| Field | Value |
|---|---|
| Primary Code | K75.4 |
| Adverse Effect Code (Minocycline) | T36.4X5A |
| Adverse Effect Code (Nitrofurantoin) | T37.8X5A |
| Adverse Effect Code (Immune Checkpoint Inhibitors) | T45.1X5A |
| Personal History Code | Z87.19 |
| Liver Biopsy CPT | 47000 |
| Autoantibody Tests | ANA, SMA, anti-LKM-1 |
The primary ICD-10-CM code for autoimmune hepatitis is K75.4. This code is used for the diagnosis of autoimmune hepatitis regardless of the cause, but when drug-induced, an additional code from the T36-T50 range is required to identify the specific drug and adverse effect.
Drug-induced autoimmune hepatitis is coded by combining K75.4 (autoimmune hepatitis) with a code from the T36-T50 range that specifies the drug and the adverse effect. For example, minocycline adverse effects are coded as T36.4X5A, nitrofurantoin as T37.8X5A, and immune checkpoint inhibitors as T45.1X5A. The external cause code is not required for adverse effects.
The onset varies by drug. For minocycline and nitrofurantoin, it typically occurs after months to years of therapy. For immune checkpoint inhibitors, it can occur within 6 to 14 weeks after the first dose, though later presentations are possible. Temporal association with drug initiation and improvement upon withdrawal support the diagnosis.
Commonly implicated drugs include minocycline, nitrofurantoin, hydralazine, methyldopa, TNF-α inhibitors (e.g., infliximab, adalimumab), and immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab, ipilimumab). These agents can trigger autoimmune hepatitis through various mechanisms, including hapten formation and immune checkpoint blockade.
No. Submission requests an initial records screening only and does not create an medical context-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.